Capmatinib
Tabrecta · MET inhibitor
Reversible creatinine rise and edema.
Verzenio · Abema
CDK4/6 inhibitor · approved 2017 · 8 citations · FAERS AKI reporting ROR 1.63 (95% CI 1.47–1.82, 325 AKI reports)
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A CDK4/6 inhibitor that raises creatinine by blocking its tubular secretion — a 'pseudo-AKI' with intact true GFR.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
A benign serum-creatinine rise occurs in roughly one-fifth of patients (~20% in a single-center series; a class effect across CDK4/6 inhibitors), almost always grade 1–2 and without true GFR loss. In a dedicated CDK4/6-inhibitor cohort, ~73% of creatinine rises were confirmed pseudo-AKI by cystatin C–based eGFR.Source: Ly et al., J Oncol Pharm Pract 2026 (~20% abemaciclib)
Creatinine rise appears early within the first weeks (median onset ~3 weeks), stays stable thereafter, and reverses on discontinuation.
Distilled from: “Early — within the first weeks (median onset ~3 weeks), stable thereafter, reversible on discontinuation.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Reversible serum creatinine rise ~15-40% over baseline from inhibition of tubular OCT2/MATE1/MATE2-K secretion; measured GFR and tubular-injury biomarkers (NGAL, KIM-1, cystatin C) unchanged PMID 30449032 (opens PubMed in a new tab)
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Tap a signature to trace where it strikes the nephron.
Representative incidence
Pseudo-AKI strikes: Proximal Tubule.
Pseudo-AKI
The great mimic — a rise in creatinine from blocked tubular secretion (OCT2/MATE), NOT true injury. The GFR is intact; confirm with cystatin C before stopping effective therapy.
Cyclin-dependent kinase 4/6 inhibitor that prevents RB phosphorylation and arrests the G1–S cell-cycle transition, used with endocrine therapy in HR-positive, HER2-negative breast cancer (early and advanced); among CDK4/6 inhibitors it has the most continuous dosing and the strongest GI (diarrhea) signal.
7 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Quoted verbatim from this agent's current FDA label (Sep 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
No dosage adjustment is required for patients with mild or moderate renal impairment (CLcr ≥30-89 mL/min, estimated by Cockcroft-Gault [C-G]). The pharmacokinetics of abemaciclib in patients with severe renal impairment (CLcr <30 mL/min, C-G), end stage renal disease, or in patients on dialysis is unknown [see Clinical Pharmacology ( 12.3 )] .
Kidney rows of the label's dosage tables
From the Verzenio label (Sep 2026) · DailyMed
No row of this label's 7 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 21,412 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
1,516 of 21,412 reports
Reported with hospitalization
4,526 of 21,412 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 2 of the 21,412 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Abemaciclib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Tabrecta · MET inhibitor
Reversible creatinine rise and edema.
Tepmetko · MET inhibitor
Creatinine rise and peripheral edema.
Voranigo · Mutant IDH1/2 inhibitor
A brain-penetrant IDH inhibitor whose kidney footprint is a benign creatinine bump, not true AKI.
Inluriyo · Oral selective estrogen-receptor degrader (SERD)
2025 brain-penetrant oral SERD; renally benign — the only wrinkle is the benign abemaciclib creatinine rise in the combo.
Hernexeos · HER2 TKI
HER2 exon20 TKI (2025); creatinine rise likely a secretion artifact.
Alecensa · ALK TKI
Creatinine rise via reduced tubular secretion.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Abemaciclib’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Abemaciclib; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 18 clinical records among all 23 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.